<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Personalized medicine is pharmaceuticals or biological treatments paired with diagnostic tests (companion tests) that personalized the medicine in question with genetics or genetic signatures </plain></SENT>
<SENT sid="1" pm="."><plain>Target-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutics has remarkably improved the outcomes of patients and represents the frontline approach to treatments in <z:hpo ids='HP_0002664'>oncology</z:hpo> today </plain></SENT>
<SENT sid="2" pm="."><plain>The molecular basis governing the deveLopment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is well established </plain></SENT>
<SENT sid="3" pm="."><plain>K-ras is one of the early key components in the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and is involved in many signal transduction pathways of the epidermal growth factor receptor--EGFR </plain></SENT>
<SENT sid="4" pm="."><plain>Both cetuximab and panitumumab, EGFR monoclonal antibodies, are approved for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with mutations in oncogene K-ras are not considered candidates for those treatments </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, identifying patients with K-ras mutations is critical prior to treatment selection </plain></SENT>
<SENT sid="7" pm="."><plain>In Israel, cetuximab is approved as third line therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients and K-ras testing is required before choosing therapy </plain></SENT>
<SENT sid="8" pm="."><plain>The study by Segal et at, pubLished in this issue, assessed the prevalence of molecular types of K-ras mutations in stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients who failed two lines of treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Those results revealed a pattern similar to that seen in other studies </plain></SENT>
<SENT sid="10" pm="."><plain>This editorial discusses the results of this study in the context of personalized medicine and presents the need for promoting the understanding and use of personalized medicine within the Israeli healthcare system </plain></SENT>
<SENT sid="11" pm="."><plain>Use of personalized medicine Leads to better health outcomes and may result in saving healthcare costs </plain></SENT>
</text></document>